Nuveen Credit Opportunities 2022 Target Term Fund
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JCO research report →
Price Chart
About the company
The Nuveen Credit Opportunities 2022 Target Term Fund (JCO) is structured as a closed-end mutual fund, focusing its investments within the fixed income sector. Established by Nuveen Investments, Inc. , the fund receives joint oversight from Nuveen Fund Advisors, LLC, and Symphony Asset Management.
- IPO
- 2017
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on JCO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $220.81M
- P/E
- 24.84
- PEG
- 0.25
- P/S
- 24.55
- P/B
- 0.97
- EV/EBITDA
- 0.00
- Div Yield
- 5.60%
- Gross Margin
- 100.00%
- Op Margin
- 97.94%
- Net Margin
- 97.94%
- ROE
- 3.86%
- ROIC
- 3.88%
Latest fiscal year · YoY change
- Revenue
- $8.99M+143.8%
- Gross Profit
- $8.99M+143.8%
- Op Income
- $8.81M
- Net Income
- $8.81M+142.4%
- EPS
- $0.32+142.7%
- OCF Growth
- +100.9%
- FCF Growth
- +100.9%
- 52W High
- $7.96
- 52W Low
- $7.94
- 50D MA
- $7.95
- 200D MA
- $7.95
- Beta
- 0.00
- RSI (14)
- 35
- Avg Volume
- 0
No earnings-call transcripts are available for JCO yet.
- Free Float
- 0.0%
- Shares Outstanding
- 27.77M
- Float Shares
- 0
of shares held by institutions
35 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bb&T Securities, LLC | 89.73K | ▲ 6.26K |
| Advisor Group, Inc. | 29.20K | ▼ 19.50K |
| Ladenburg Thalmann Financial Services Inc. | 6.25K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 14, 22 | McCann John M. | other | 0 |
| Jun 2, 21 | Medero Joanne | other | 0 |
| Jun 2, 21 | Lancellotta Amy B.R. | other | 0 |
| Jan 12, 21 | Nuveen Fund Advisors, LLC | sell | 10,160 |
| Nov 16, 20 | Thornton Matthew III | other | 0 |
| Aug 17, 20 | Fitzpatrick Jake John | other | 0 |
| Feb 27, 20 | Morgan Deann | other | 0 |
| Oct 7, 19 | Meissner Jon Scott | other | 0 |
| Aug 8, 19 | Longerstaey Jacques M | other | 0 |
| Aug 8, 19 | Lockhart Brian J | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JCO coverage
Recent articles, reports, and earnings notes.
No research on JCO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JCO report →RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
gurufocus.com · May 31
Daily Journal Corp. (S.C.) (NASDAQ:DJCO) and American Community Newspapers (OTCMKTS:ACNI) Critical Review
defenseworld.net · Nov 3
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
prnewswire.com · Aug 29
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
prnewswire.com · Jun 2
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
prnewswire.com · Jun 1
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
globenewswire.com · May 16
Nuveen Credit Opportunities 2022 Target Term Fund Announces Termination and Liquidation
businesswire.com · Jun 2
Nuveen Credit Opportunities 2022 Target Term Fund Declares Special Distribution
businesswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.